>>Signaling Pathways>> Apoptosis>> Other Apoptosis>>Iberdomide

Iberdomide (Synonyms: CC-220)

Catalog No.GC19195

Iberdomide(CC-220)는 cereblon 결합 친화도에 대해 IC50이 ~150nM인 경구 활성 및 강력한 cereblon(CRBN) E3 리가제 조절제(CELMoD)입니다.

Products are for research use only. Not for human use. We do not sell to patients.

Iberdomide Chemical Structure

Cas No.: 1323403-33-3

Size 가격 재고 수량
2mg
US$66.00
재고 있음
5mg
US$104.00
재고 있음
10mg
US$171.00
재고 있음
25mg
US$348.00
재고 있음
50mg
US$549.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

Iberdomide (CC-220) is a cereblon modulator with an IC50 of 60 nM.

Lenalidomide and pomalidomide, targeting cereblon, are immunomodulatory drugs that are clinically effective in the treatment of cancer, including newly diagnosed and relapsed multiple myeloma. Iberdomide contains a glutarimide ring that binds in the try-tryptophan pocket of cereblon and an isoindolinone ring that can interact with both cereblon and substrates. Treatment with Iberdomide results in the loss of Ikaros and Aiolos protein levels with EC50s of 1 nM and 0.5 nM [1].

Iberdomide (CC-220) is currently in phase 2 clinical trials for the treatment of systematic lupus erythematosus (SLE) and phase 1b/2a clinical trials for relapsed and refractory multiple myeloma (MM)[1].

References:
[1]. Matyskiela ME, et al. A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos. J Med Chem. 2017 Apr 20.

리뷰

Review for Iberdomide

Average Rating: 5 ★★★★★ (Based on Reviews and 19 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Iberdomide

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.